Philippe Close - Concepedia

Concepedia

Author

Philippe Close

Novartis (Switzerland)

Also Known As

P Close, P. Close, PHILIPPE CLOSE, Philippe Close

24

Publications

1.2K

Citations

12

H-Index

22

Concepts

All Affiliations

Novartis (Switzerland)University of Gothenburg KU Leuven University of Münster

PC

About

Philippe Close is an author at Novartis (Switzerland) specializing in hematology, medicine, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	315
2	Pharmacology	4	4	269
3	Orthopaedics	2	2	222
4	Health Sciences	1	1	46
5	Medical Laboratory Science	1	1	13

Philippe Close

×

13

Publications

1.2K

Citations

12

H-Index

	Year	Citations
A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement Bengt I. Eriksson, Peter Kälebo, Patrick Mouret, New England Journal of Medicine	1997	371
Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393 Bengt I. Eriksson, P Kälebo, B Zachrisson, The Lancet ThrombopoiesisThrombosisVenous ThrombosisCardiovascular DiseaseAtherosclerosis	1996	176
Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement* Bengt I. Eriksson, Steffan Ekman, Siv Lindbratt, Journal of Bone and Joint Surgery	1997	138
Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Arjan A. van den Bos, Jaap W. Deckers, Guy R. Heyndrickx, Circulation	1993	113
Biologic effects of recombinant hirudin (CGP 39393) in human volunteers Marc Verstraete, J Kienast, Matthias Siebeck, Journal of the American College of Cardiology MedicineHuman VolunteersHematologyHemostasisPharmacotherapy	1993	70
Clinical Pharmacology of Intravenously Administered Recombinant Desulfatohirudin (CGP 39393) in Healthy Volunteers GA Marbet, M Verstraete, W. Kienast, Journal of Cardiovascular Pharmacology	1993	55
Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin Gilbert Lefèvre, Martine Duval, Sonia Gauron, Clinical Pharmacology & Therapeutics	1997	52
Direct Thrombin Inhibition with Rec-Hirudin CGP 39393 as Prophylaxis of Thromboembolie Complications after Total Hip Replacement Bengt I. Eriksson, Peter Kälebo, Steffan Ekman, Thrombosis and Haemostasis Direct Thrombin InhibitionCgp 39393SurgeryPharmacotherapyMg Cgp 39393	1994	46
Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group). Philippe Close, J. Bichler, Roger Kerry, PubMed	1994	39
Percentage of Inadequate Phlebograms and Observer Agreement in Thromboprophylactic Multicenter Trials Using Standardized Methodology and Central Assessment Peter Kälebo, Steffan Ekman, Siv Lindbratt, Thrombosis and Haemostasis	1996	39

Page 1